electroCore Submits Emergency Use Authorization Application to Allow the Study and Use of gammaCore nVNS Therapy to Treat Respiratory Symptoms Associated with COVID-19
electroCore, Inc. (ECOR)
Last electrocore, inc. earnings: 3/23 04:05 pm
Check Earnings Report
Company Research
Source: GlobeNewswire
BASKING RIDGE, N.J., April 02, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the company has submitted an Emergency Use Authorization (EUA) application to the U.S. Food and Drug Administration (FDA) to facilitate the study and clinical use of its gammaCore SapphireTM non-invasive vagus nerve stimulation therapy, or nVNS, for respiratory symptoms associated with COVID-19. The EUA includes data from early clinical and non-clinical work that examined the use of the company’s VNS, including non-invasive therapy, in several pilot studies that involved patients with a variety of respiratory disorders. These studies suggest a possible benefit for patients with respiratory distress associated with COVID-19. Additionally, gammaCore’s strong safety and tolerability profile suggest that it would be safe to study or use in patients with COVID-19. Peter Staats, MD, MBA, co-founder and Chief Medical
Show less
Read more
Impact Snapshot
Event Time:
ECOR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ECOR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ECOR alerts
High impacting electroCore, Inc. news events
Weekly update
A roundup of the hottest topics
ECOR
News
- electroCore, Inc. (NASDAQ: ECOR) had its price target raised by analysts at HC Wainwright from $22.00 to $25.00. They now have a "buy" rating on the stock.MarketBeat
- electroCore to Acquire NeuroMetrix, Gaining Access to its Quell Platform and Positioning Itself as a Significant Player in Non-Invasive Bioelectronic Medicine and WellnessGlobeNewswire
- electroCore’s Truvaga™ Plus Wins Woman’s World Magazine 50 over 50 AwardGlobeNewswire
- electroCore Donates gammaCore Sapphire for Real World Evaluation of nVNS in Trauma Among IsraelisGlobeNewswire
- electroCore to Participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 21GlobeNewswire
ECOR
Earnings
- 11/13/24 - Miss
ECOR
Sec Filings
- 12/17/24 - Form 8-K
- 11/29/24 - Form 424B5
- 11/29/24 - Form 8-K
- ECOR's page on the SEC website